Forcyte Biotechnologies
DefunctYC W21Los Angeles, US · Founded 2017 · Delaware corporation · 5 employees · 3 known investors
Forcyte Biotechnologies develops drug screening tools that measure cell contractility to identify therapeutic candidates for diseases driven by abnormal cellular force generation, such as asthma, fibrosis, and hypertension.
Founders & leadership· Y Combinator alumni (W21)
Forcyte Biotechnologies was founded in 2017 by Ivan Pushkarsky and Dino Di Carlo.
IP
Ivan PushkarskyinCEO & Co-Founder2017–2026Dino Di Carlo. He has been involved in biotechnology development since 2013, with publications in peer-reviewed journals and experience securing SBIR grants and managing technology transfer.
DD
Dino Di Carloin𝕏Co-Founder and Board Member2017–2026Dino Di Carlo is a professor of engineering and medicine at UCLA and holds an endowed chair position. He has co-founded multiple life science startups spanning research tools, diagnostics, medical devices, and pharmaceuticals, and holds over 50 patents in areas including microfluidics, nanosystems, and single-cell analysis.
Investors · 3
Reported raises · per SEC filings
Form D private placements$160K disclosed across 1 round · 2018
▶$160KraisedJan 2019 · 3 investors · Other TechnologyRule 506(b)
▶$160KraisedJan 2019 · 3 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Ivan PushkarskyExecutive Officer
- Offering amount
- $2M
- Amount sold
- $160K
- Minimum investment
- $25K
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $394.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $350K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $288K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Forcyte Biotechnologies do?
- Forcyte Biotechnologies develops drug screening tools that measure cell contractility to identify therapeutic candidates for diseases driven by abnormal cellular force generation, such as asthma, fibrosis, and hypertension.
- Who founded Forcyte Biotechnologies?
- Forcyte Biotechnologies was founded by Ivan Pushkarsky, Dino Di Carlo in 2017.
- Who are Forcyte Biotechnologies's investors?
- Forcyte Biotechnologies's investors include Sprint Vc, Y Combinator, Acequia Capital (AceCap).
- How much funding has Forcyte Biotechnologies raised?
- Forcyte Biotechnologies has disclosed $160K raised across 1 round.
- Where is Forcyte Biotechnologies headquartered?
- Forcyte Biotechnologies is headquartered in Los Angeles, US.